The LWNVIVAT (Limiting West Nile Virus Impact by Novel Vaccines And Therapeutics Approaches) project is a European Union-funded initiative aiming to develop an effective recombinant vaccine and therapeutic antibodies against the West Nile virus infection. Coordinated by the IrsiCaixa AIDS Research Institute, the project brings together a consortium of seven partners across Europe, including research centres and a pharmaceutical company. LWNVIVAT is utilizing computational tools to develop a recombinant vaccine and therapeutic antibodies targeting the West Nile virus, triggering an immune response that covers all variants. The project will also assess the efficacy of the developed antigens using in vitro, ex vivo and in vivo models.